 I. To evaluate the safety and tolerability of high dose interleukin 2 aldesleukin in combination with entinostat in patients with metastatic renal cell carcinoma RCC. Phase I II. To monitor toxicity and estimate the efficacy of high dose aldesleukin combined with entinostat in patients with metastatic RCC. Phase II 